Frontiers in Oncology (Oct 2021)
Patient-Derived Xenografts Are a Reliable Preclinical Model for the Personalized Treatment of Epithelial Ovarian Cancer
- Jiayu Chen,
- Jiayu Chen,
- Ying Jin,
- Ying Jin,
- Siyi Li,
- Siyi Li,
- Cui Qiao,
- Cui Qiao,
- Xinxin Peng,
- Yan Li,
- Yan Li,
- Yu Gu,
- Yu Gu,
- Wei Wang,
- Wei Wang,
- Yan You,
- Jie Yin,
- Jie Yin,
- Ying Shan,
- Ying Shan,
- Yong-Xue Wang,
- Yong-Xue Wang,
- Meng Qin,
- Meng Qin,
- Hongyue Li,
- Yan Cai,
- Yu Dong,
- Siying Peng,
- Lingya Pan,
- Lingya Pan
Affiliations
- Jiayu Chen
- Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
- Jiayu Chen
- National Clinical Research Center for Obstetric & Gynecologic Diseases, Beijing, China
- Ying Jin
- Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
- Ying Jin
- National Clinical Research Center for Obstetric & Gynecologic Diseases, Beijing, China
- Siyi Li
- Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
- Siyi Li
- National Clinical Research Center for Obstetric & Gynecologic Diseases, Beijing, China
- Cui Qiao
- National Clinical Research Center for Obstetric & Gynecologic Diseases, Beijing, China
- Cui Qiao
- Beijing IDMO Co., Ltd., Beijing, China
- Xinxin Peng
- The Bioinformatics Department, Precision Scientific (Beijing) Co., Ltd., Beijing, China
- Yan Li
- Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
- Yan Li
- National Clinical Research Center for Obstetric & Gynecologic Diseases, Beijing, China
- Yu Gu
- Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
- Yu Gu
- National Clinical Research Center for Obstetric & Gynecologic Diseases, Beijing, China
- Wei Wang
- Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
- Wei Wang
- National Clinical Research Center for Obstetric & Gynecologic Diseases, Beijing, China
- Yan You
- Department of Pathology, Peking Union Medical College Hospital, Beijing, China
- Jie Yin
- Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
- Jie Yin
- National Clinical Research Center for Obstetric & Gynecologic Diseases, Beijing, China
- Ying Shan
- Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
- Ying Shan
- National Clinical Research Center for Obstetric & Gynecologic Diseases, Beijing, China
- Yong-Xue Wang
- Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
- Yong-Xue Wang
- National Clinical Research Center for Obstetric & Gynecologic Diseases, Beijing, China
- Meng Qin
- Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
- Meng Qin
- National Clinical Research Center for Obstetric & Gynecologic Diseases, Beijing, China
- Hongyue Li
- The Bioinformatics Department, Precision Scientific (Beijing) Co., Ltd., Beijing, China
- Yan Cai
- Department of Obstetrics and Gynecology, Beijing Cancer Hospital, Beijing, China
- Yu Dong
- The Medical Department, Precision Scientific (Beijing) Co., Ltd., Beijing, China
- Siying Peng
- Beijing IDMO Co., Ltd., Beijing, China
- Lingya Pan
- Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
- Lingya Pan
- National Clinical Research Center for Obstetric & Gynecologic Diseases, Beijing, China
- DOI
- https://doi.org/10.3389/fonc.2021.744256
- Journal volume & issue
-
Vol. 11
Abstract
To generate robust patient-derived xenograft (PDX) models for epithelial ovarian cancer (EOC), analyze the resemblance of PDX models to the original tumors, and explore factors affecting engraftment rates, fresh cancer tissues from a consecutive cohort of 158 patients with EOC were collected to construct subcutaneous PDX models. Paired samples of original tumors and PDX tumors were compared at the genome, transcriptome, protein levels, and the platinum-based chemotherapy response was evaluated to ensure the reliability of the PDXs. Univariate and multivariate analyses were used to determine the factors affecting the engraftment rates. The engraftment success rate was 58.23% (92/158) over 3–6 months. The Ki-67 index and receiving neoadjuvant chemotherapy can affect the engraftment rate in primary patients. The PDX models generated in this study were found to retain the histomorphology, protein expression, and genetic alteration patterns of the original tumors, despite the transcriptomic differences observed. Clinically, the PDX models demonstrated a high degree of similarity with patients in terms of the chemotherapy response and could predict prognosis. Thus, the PDX model can be considered a promising and reliable preclinical tool for personalized and precise treatment.
Keywords
